title: Rebamipide does not interfere with the antitumor effect of radiotherapy or chemotherapy in human oral tumor-bearing nude mice.
abstract: Recent studies have shown that rebamipide, which suppresses reactive oxygen species, prevents chemoradiotherapy-induced oral mucositis in patients with head and neck cancers. However, anticancer action of radiotherapy and chemotherapy is believed to be partially associated with generation of reactive oxygen species. The aim of this study was to determine whether rebamipide interferes with the antitumor action of radiotherapy and chemotherapy. The effect of rebamipide on tumor cell growth was investigated using a human oral squamous carcinoma cell line, HSC-2, in vitro and in vivo. Rebamipide showed no significant effect on cell or tumor growth in HSC-2 tumor-bearing nude mice. Influences of rebamipide on the antitumor action of radiotherapy and of chemotherapy with cisplatin or docetaxel were investigated using the same animal model. In radiotherapy, the tumor was treated with 2.5 Gy of X-rays for 5 days, and rebamipide (300 mg/kg p.o.) was administered during irradiation periods. In chemotherapy, tumor-bearing mice were treated once with cisplatin (8 mg/kg, i.v.) or docetaxel (15 mg/kg i.v.) and rebamipide (300 mg/kg p.o.) was administered for 5 days following the antitumor drug treatment. Rebamipide did not interfere with the antitumor action of radiotherapy and chemotherapy.
authors: Third Institute of New Drug Discovery, Otsuka Pharmaceutical Co., Ltd., Japan.
authors: Masafumi
authors: M
authors: Shibamori
authors: Third Institute of New Drug Discovery, Otsuka Pharmaceutical Co., Ltd., Japan.
authors: Masayuki
authors: M
authors: Sato
authors: Third Institute of New Drug Discovery, Otsuka Pharmaceutical Co., Ltd., Japan.
authors: Naoya
authors: N
authors: Uematsu
authors: Third Institute of New Drug Discovery, Otsuka Pharmaceutical Co., Ltd., Japan.
authors: Takako
authors: T
authors: Nakashima
authors: Tokushima Research Institute, Otsuka Pharmaceutical Co., Ltd., Japan.
authors: Asuka
authors: A
authors: Sato
authors: Tokushima Research Institute, Otsuka Pharmaceutical Co., Ltd., Japan.
authors: Yoshiya
authors: Y
authors: Yamamura
authors: Tokushima Research Institute, Otsuka Pharmaceutical Co., Ltd., Japan.
authors: Hiroyuki
authors: H
authors: Sasabe
authors: Tokushima Research Institute, Otsuka Pharmaceutical Co., Ltd., Japan.
authors: Ken
authors: K
authors: Umehara
authors: Third Institute of New Drug Discovery, Otsuka Pharmaceutical Co., Ltd., Japan. Electronic address: sakuraik@otsuka.jp.
authors: Kazushi
authors: K
authors: Sakurai
mesh_terms: D000409:Alanine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000975:Antioxidants / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000532:radiotherapy*; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D004195:Disease Models, Animal; D000077143:Docetaxel; D004347:Drug Interactions; D005260:Female; D006801:Humans; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D015363:Quinolones / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D011878:Radiotherapy / Q000009:adverse effects; D013280:Stomatitis / Q000209:etiology / Q000517:prevention & control; D043823:Taxoids / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D000975:Antioxidants; D015363:Quinolones; D043823:Taxoids; D000077143:Docetaxel; C052785:rebamipide; D000409:Alanine; D002945:Cisplatin
keywords: Chemotherapy; HSC-2 tumor-bearing nude mice; Radiotherapy; Reactive oxygen species; Rebamipide